PRMT5 regulates ATF4 transcript splicing and oxidative stress response.


Journal

Redox biology
ISSN: 2213-2317
Titre abrégé: Redox Biol
Pays: Netherlands
ID NLM: 101605639

Informations de publication

Date de publication:
05 2022
Historique:
received: 11 01 2022
revised: 18 02 2022
accepted: 08 03 2022
pubmed: 20 3 2022
medline: 20 4 2022
entrez: 19 3 2022
Statut: ppublish

Résumé

Protein methyltransferase 5 (PRMT5) symmetrically dimethylates arginine residues leading to regulation of transcription and splicing programs. Although PRMT5 has emerged as an attractive oncology target, the molecular determinants of PRMT5 dependency in cancer remain incompletely understood. Our transcriptomic analysis identified PRMT5 regulation of the activating transcription factor 4 (ATF4) pathway in acute myelogenous leukemia (AML). PRMT5 inhibition resulted in the expression of unstable, intron-retaining ATF4 mRNA that is detained in the nucleus. Concurrently, the decrease in the spliced cytoplasmic transcript of ATF4 led to lower levels of ATF4 protein and downregulation of ATF4 target genes. Upon loss of functional PRMT5, cells with low ATF4 displayed increased oxidative stress, growth arrest, and cellular senescence. Interestingly, leukemia cells with EVI1 oncogene overexpression demonstrated dependence on PRMT5 function. EVI1 and ATF4 regulated gene signatures were inversely correlated. We show that EVI1-high AML cells have reduced ATF4 levels, elevated baseline reactive oxygen species and increased sensitivity to PRMT5 inhibition. Thus, EVI1-high cells demonstrate dependence on PRMT5 function and regulation of oxidative stress response. Overall, our findings identify the PRMT5-ATF4 axis to be safeguarding the cellular redox balance that is especially important in high oxidative stress states, such as those that occur with EVI1 overexpression.

Identifiants

pubmed: 35305370
pii: S2213-2317(22)00054-4
doi: 10.1016/j.redox.2022.102282
pmc: PMC8933703
pii:
doi:

Substances chimiques

ATF4 protein, human 0
Activating Transcription Factor 4 145891-90-3
Protein Methyltransferases EC 2.1.1.-
PRMT5 protein, human EC 2.1.1.319
Protein-Arginine N-Methyltransferases EC 2.1.1.319

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102282

Subventions

Organisme : CIHR
ID : FDN154328
Pays : Canada
Organisme : Wellcome Trust
ID : 106169/ZZ14/Z
Pays : United Kingdom

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Auteurs

Magdalena M Szewczyk (MM)

Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.

Genna M Luciani (GM)

Department of Medical Biophysics, University of Toronto, Ontario, Canada; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Victoria Vu (V)

Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Ontario, Canada.

Alex Murison (A)

Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

David Dilworth (D)

Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.

Samir H Barghout (SH)

Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada.

Mathieu Lupien (M)

Department of Medical Biophysics, University of Toronto, Ontario, Canada; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Cheryl H Arrowsmith (CH)

Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada; Department of Medical Biophysics, University of Toronto, Ontario, Canada; Princess Margaret Cancer Centre, Toronto, Ontario, Canada.

Mark D Minden (MD)

Department of Medical Biophysics, University of Toronto, Ontario, Canada; Princess Margaret Cancer Centre, Toronto, Ontario, Canada. Electronic address: Mark.Minden@uhn.ca.

Dalia Barsyte-Lovejoy (D)

Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, M5S 1A8, Canada. Electronic address: d.barsyte@utoronto.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH